Hydrabad based phara major  Dr. Reddy's Laboratories on Monday announced the commercial launch of 2-deoxy-D-glucose (2-DG) for treatment of Covid-19. Accordingly, the company will supply the drug to major government as well as private hospitals across India. In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India.

Dr. Reddy claims that 2-DG has a purity of 99.5% and is being sold commercially under the brand name 2DG. The maximum retail price (MRP) of each sachet has been fixed at Rs. 990,with a subsidized rate offered to government institutions. Enquiries for 2DGTMcan be sent to 2DG@drreddys.com.

2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's.2-DG is an oral drug.

It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe Covid-19 patients as an adjunct therapy to the existing standard of care. Emergency use approval for anti-Covid-19 therapeutic application of the drug was granted on May 1, 2021.

AstraZeneca kicks up trials for custom-made booster vaccine against Covid Beta variant

Edible Cholera vaccine develops from powdered rice by Japanese researchers

Research discovers structural changes in the SARS-CoV-2 Alpha, Beta variants